A new clinical trial will investigate whether a simple blood test could help detect breast cancer as early as Stage I.
|Videos|April 30, 2020
Dr. O'Regan on Breast Cancer Treatment Considerations During the COVID-19 Crisis
Author(s)OncLive Staff
Ruth O’Regan, MD, provides insight on how the COVID-19 crisis is impacting the care of patients with breast cancer.
Advertisement
Ruth O’Regan, MD, provides insight on how the COVID-19 crisis is impacting the care of patients with breast cancer. She also shed light on cardiac toxicities associated with HER2-directed therapy and what those events might mean with regard to treatment decisions in light of the pandemic.
Please visit
Advertisement
Related to this article
Phase 3 data showed a significant PFS improvement with trastuzumab pamirtecan vs chemotherapy in HR-positive, HER2-low metastatic breast cancer.
An exploratory TROPION-Breast02 analysis showed CNS PFS and intracranial response benefits with datopotamab deruxtecan in TNBC with brain metastases.
Abemaciclib plus fulvestrant showed a numerical yet nonsignificant overall survival trend after CDK4/6 inhibitor progression in final postMONARCH data.
Selective CDK4 inhibitor atirmociclib plus fulvestrant reduced risk of progression or death by 40% vs investigator's choice of therapy in the phase 2 FOURLIGHT-1 trial.
Signifcant efficacy improvements were shown with iza-bren in HR+/HER2-negative breast cancer.
A protein called MPP8 helps drive chemotherapy resistance in the most-aggressive subtype of breast cancer, and suppressing its expression has the potential to improve treatment outcomes.
Breast cancer experts address frequently asked questions on adjuvant and metastatic CDK4/6 inhibitor selection in HR-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
Petosemtamab Plus Pembrolizumab Hits Phase 3 OS, ORR Primary End Points in PD-L1+ R/M HNSCC
4
Sac-TMT Plus Pembrolizumab Improves PFS in PD-L1–Negative Nonsquamous NSCLC
5